Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 27, 2021 07:30 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences appoints renowned scientist, Dr. David Wishart as Chief Physics Officer

TORONTO, and CAMBRIDGE, Mass., May 27, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody...
May 25, 2021 07:30 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences initiates commercialization of COVID-19 serology assay

TORONTO and CAMBRIDGE, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN); (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody...
May 21, 2021 08:30 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences re-initiates path to IND for PMN310 with producer cell line development

TORONTO and CAMBRIDGE, Mass., May 21, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN); (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody...
May 19, 2021 06:30 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences appoints accomplished biotechnology executive, Neil Warma, to its Board of Directors

TORONTO and CAMBRIDGE, Mass., May 19, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN); (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody...
May 14, 2021 07:00 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences Announces First Quarter 2021 Results

TORONTO and CAMBRIDGE, Mass., May 14, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS or the Company”), a biotechnology company focused on the discovery and...
May 12, 2021 06:30 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences appoints renowned neuroscientist, Dr. Rudolph Tanzi, as Chair of Scientific Advisory Board

TORONTO and CAMBRIDGE, Mass., May 12, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN); (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody...
March 31, 2021 07:30 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences Announces Fiscal Year 2020 Results

TORONTO and CAMBRIDGE, Mass., March 31, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS or the Company”), a biotechnology company focused on the discovery and...
March 22, 2021 10:44 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences Completes US$7M (CDN$8.75M) Financing with Distinguished Group of Boston Based Investors

TORONTO and CAMBRIDGE, Mass., March 22, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody...
February 02, 2021 08:30 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences Offers Perspectives on Recent Progress in the Alzheimer’s/Amyloid Field

Two positive events in January support PMN310 “best in class” positioning TORONTO and CAMBRIDGE, Mass., Feb. 02, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a...
January 12, 2021 06:30 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences Announces Strategic Priorities for 2021

TORONTO and CAMBRIDGE, Mass., Jan. 12, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody...